Aptahem

Aptahem CROIC

The Cash Return on Invested Capital (CROIC) of Aptahem (APTA.SL) as of Nov 2, 2026 is -27.43 %. In the previous year, Cash Return on Invested Capital (CROIC) was -39.24 % — a change of -30.10% (higher).

CROIC

-27.43 %

YoY

-30.10%

Last updated:

Cash Return on Invested Capital (CROIC) of Aptahem is 2024 -27.43 % . Cash Return on Invested Capital (CROIC) of Aptahem was 2023 -39.24 % . It decreases by -30.10% higher compared to the previous year.

The Aptahem CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2017
-51.88 SEK
Jan 1, 2018
-55.72 SEK
Jan 1, 2019
-80.41 SEK
Jan 1, 2020
-76.83 SEK
Jan 1, 2021
-71.37 SEK
Jan 1, 2022
-70.15 SEK
Jan 1, 2023
-39.24 SEK
Jan 1, 2024
-27.43 SEK
The Aptahem CROIC history
YEARCROICYoY
-27.43 %-30.10%
-39.24 %-44.06%
-70.15 %-1.70%
-71.37 %-7.12%
-76.83 %-4.45%
-80.41 %+44.32%
-55.72 %+7.40%
-51.88 %+15.36%
-44.97 %-64.71%
-127.43 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptahem Stock analysis

What does Aptahem do? Aptahem AB is a biotechnology company based in Malmö, Sweden, operating within the healthcare sector. The company focuses on developing drug candidates aimed at treating and preventing diseases caused by blood vessel blockages due to blood clots, including conditions such as deep vein thrombosis, stroke, and heart failure. Aptahem AB went public through an IPO on April 17, 2015, and is listed under the ticker APTA.SL with ISIN SE0022447173. The company's headquarters are located in Malmö, a city in the Skåne region of Sweden. While the source material mentions a founding year of 2014, this detail is not confirmed by the provided facts, so it is omitted. Aptahem AB's website, aptahem.com, serves as the primary online resource for information about the company's activities and developments. The company operates in the biotechnology industry, specializing in therapeutic solutions for cardiovascular and related conditions. As a publicly traded entity, Aptahem AB is subject to the regulatory requirements of the Swedish financial market. The firm's strategic focus lies in addressing unmet medical needs through innovative drug development, targeting conditions that significantly impact patient outcomes and healthcare systems. The company's operations are centered in Malmö, reflecting its commitment to contributing to the biotechnology ecosystem in southern Sweden. Aptahem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptahem stock

Cash Return on Invested Capital (CROIC) of Aptahem is -27.43 % in 2024.

Cash Return on Invested Capital (CROIC) of Aptahem changed from -39.24 % to -27.43 %, representing a -30.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) Aptahem since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s Aptahem with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Aptahem

All Key Metrics — Aptahem